Asarina Pharma IPO oversubscribed 175%: CEO welcomes new shareholders
With its IPO listing oversubscribed by 175%, Asarina Pharma is firmly in the investor and scientific spotlight. Here, CEO Peter Nordkild shares upcoming research and business highlights with the company’s new shareholders."The major commitments we received from large institutional investors in North America, Europe and Sweden reflect a historic shift in attitudes towards women’s health,” says Asarina Pharma CEO Peter Nordkild. “With a strong hereditary element PMDD has gone untreated and undiagnosed for generations. Our business strategy, combined with the pedigree of our research, means a